MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In


News Categories




NIH Report: Treatment for Novel Coronavirus Shows Promise in Early Lab Tests

Ribavirin and interferon inhibit virus replication in cell culture (Apr. 18)

Scientists at the National Institutes of Health (NIH) studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon (IFN)-alpha 2b, can stop the virus from replicating in laboratory-grown cells. The results suggest that the drug combination could be used to treat patients infected with the new coronavirus, the agency says, but more research is needed to confirm this preliminary finding.

The study was published in the April 18 issue of Scientific Reports.

The new coronavirus, called nCoV, was first identified in Saudi Arabia in September 2012. As of April 16, 2013, the World Health Organization (WHO) has reported 17 cases with 11 deaths, primarily in the Middle East. Although the case count is small, the new coronavirus has been transmitted from human to human in situations where people — mainly family members — have had close contact with those infected.

Because of the high fatality rate, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, saw an urgent need to identify therapeutic options. In laboratory tests using cells from two species of monkey, the researchers found that either ribavirin or IFN-alpha 2b — drugs currently approved for the treatment of hepatitis C — inhibited nCoV from replicating when used individually. However, the required drug concentrations exceeded what is recommended for people. By combining the two antiviral agents, the scientists established an effective treatment dose at a drug level that is achievable in humans. They plan to confirm these results in a recently developed monkey model of nCoV infection.

Source: NIAID; April 18, 2013.

More stories